AT&T and Thales Collaborate to Revolutionize IoT Deployments With New eSIM Solution
30.10.2025 13:00:00 CET | Business Wire | Press Release
With over 5.8 billion IoT cellular connections expected globally by 2030 (GSMA Intelligence) — powering everything from smart meters to wearable health trackers — the need for secure, scalable, and easy-to-manage connectivity is greater than ever. AT&T, a leader in connectivity and IoT solutions, and Thales, a global leader in advanced Cyber & Digital technologies, announce the launch of a new eSIM solution designed to help businesses remotely activate and manage IoT devices. This eSIM solution, powered by Thales Adaptive Connect (TAC), becomes a key part of AT&T’s global IoT solution, AT&T Virtual Profile Management for IoT, and can support many industries worldwide including automotive, smart cities, healthcare and utilities.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251030899315/en/
Source 123Ref
Compliant with the GSMA SGP.32 standard1, the new solution enables customers to ship connected devices anywhere in the world with one single, pre-integrated eSIM from Thales, then seamlessly activate the correct local connectivity profile remotely, eliminating the need for any physical access to it. This results in faster launches and simpler logistics for global IoT deployments. It also enables AT&T and its customers to easily manage connectivity policies, diagnostics, and subscription changes entirely over the air, through a single unified industry-certified interface.
This solution also adds advanced automation to simplify the remote eSIM management of large numbers of devices. It automates complex tasks—such as switching subscriptions or updating fleets rules—so enterprises can spend less time on logistics and operations, while bringing new products and services faster to market.
____________________ |
1 The GSMA SGP.32 standard the latest specification from the GSM Association for eSIM (embedded SIM) Remote SIM Provisioning (RSP), for the remote eSIM management of Internet of things (IoT) devices and other types of mobile device deployments. |
Thanks to these advanced features, Thales’ eSIM solution (TAC) gives companies the flexibility to localize within AT&T network partners or adjust devices’ subscriptions across large fleets without hardware changes, helping optimize costs, supply chains, coverage, and performance.
The service is now available for commercial use and supports customers worldwide.
“At AT&T, we deliver intelligent IoT solutions you can trust—highly secure, end-to-end, and built to scale,” saidCameron Coursey, VP of AT&T Connected Solutions. “Our state-of-the-art approach, paired with Thales’ solution, will help customers reduce friction and gain control of managing their own devices with reliable connectivity.”
“We are entering a new era for remote eSIM Provisioning, ready to power billions of IoT devices, and we are proud to collaborate with AT&T in delivering smarter and safer IoT connectivity around the world,” said Eva Rudin, EVP Mobile Connectivity Solutions at Thales. “With Thales Adaptive Connect, we’re ensuring that every connected device benefits from strong security, reliable service, and simplified management — from the first connection and throughout its lifetime.”
About Thales
Thales (Euronext Paris: HO) is a global leader in advanced technologies for the Defence, Aerospace, and Cyber & Digital sectors. Its portfolio of innovative products and services addresses several major challenges: sovereignty, security, sustainability and inclusion.
The Group invests more than €4 billion per year in Research & Development in key areas, particularly for critical environments, such as Artificial Intelligence, cybersecurity, quantum and cloud technologies.
Thales has more than 83,000 employees in 68 countries. In 2024, the Group generated sales of €20.6 billion.
About Thales in the U.S.
In the United States, Thales has conducted significant research and development, manufacturing, and service capabilities for more than 130 years. Today, Thales has 40 locations around the U.S., employing nearly 5,000 people. Working closely with customers and local partners, Thales is able to meet the most complex requirements for every operating environment.
About AT&T
We help more than 100 million U.S. families, friends and neighbors, plus nearly 2.5 million businesses, connect to greater possibility. From the first phone call 140+ years ago to our 5G wireless and multi-gig internet offerings today, we @ATT innovate to improve lives. For more information about AT&T Inc. (NYSE:T), please visit us at about.att.com. Investors can learn more at investors.att.com.
PLEASE VISIT
Thales Group
Download HD photos
View source version on businesswire.com: https://www.businesswire.com/news/home/20251030899315/en/
Contacts
PRESS CONTACT
Thales, Media Relations
North America
Jennifer Tumminio
jennifer.tumminio@thalesgroup.com
AT&T Corporate Communications
Veleisa Burrell
Phone: 214-773-0040
Email: veleisa.burrell@att.com
(c) 2024 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
BeOne Presents Compelling Data in Hard-to-Treat Liver and Lung Cancers at ESMO 202624.10.2026 10:15:00 CEST | Press Release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data from multiple differentiated investigational medicines across its priority solid tumor disease areas at the European Society for Medical Oncology (ESMO) Congress 2026 (October 23–27, Madrid). The presentations span gastrointestinal, lung, and breast cancers, and reflect the growing momentum of BeOne’s solid tumor franchise. Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “At ESMO, we are showing how our strategy of matching the right modality to disease biology is translating into meaningful clinical progress. Our GPC3 x 4-1BB bispecific antibody continues to be well tolerated and demonstrates durable activity with longer follow up in patients with heavily pre-treated hepatocellular carcinoma, while the first clinical data from our brain-penetrant PRMT5 inhibitor and CEA-targeting ADC expand our innovation in non-small cell lung cancer. Alongsi
Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 19:42:00 CEST | Press Release
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Society of Nephrology (ASN) Kidney Week 2026 in Denver, Colorado, and advancement of the povetacicept clinical research program in IgAN. Vertex will also host an investor event during ASN on October 23 at 6:15-7 p.m. MDT (8:15-9 p.m. EDT). Further details are below. Data being presented include a pre-specified Week 36 interim analysis of the ongoing Phase 3 RAINIER trial of povetacicept, an engineered fusion protein and dual inhibitor of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines, in immunoglobulin A nephropathy (IgAN). RAINIER met its primary endpoint, with povetacicept achieving a 52.0% reduction from baseline in proteinuria at Week 36 and a statistically significant and clinically meaningful 49.8% reduction versus placebo (
Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:19:00 CEST | Press Release
Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com
BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press Release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “Following the U.S. approval in August, these longer-term data provide further evidence supporting TEVIMBRA plus ZIIHERA and chemotherapy as the new standard of care in all first-line HER2-positive advanced gastroesophageal adenocarcinoma patients, regardless of PD-L1 sta
inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press Release
inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a leading Central Asian economy, this gives the companies a clear basis to assess autonomous ride-hailing in practice. The three companies will evaluate the technical, operational, regulatory and
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom